• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Acid-Treated Platelets May Be an Alternative to HLA-Matched Platelets for Transfusions

February 24, 2016

56777571HLA antibodies can lead to patients becoming refractory to platelet transfusions, and transfusions can be difficult when HLA-matched donors cannot be found.  Only a few case reports have examined denaturing HLA Class I antigens from platelets before transfusion, and the transfusion outcomes have been variable.  Results from a new study published in TRANSFUSION suggest that acid treatment removes 70-90% of the Class I HLA complexes.  These platelets remain viable, aggregate normally, respond normally to natural agonists, and protect platelets from HLA-antibody-mediated complement lysis and monocyte-mediated phagocytosis in vitro.  The results suggest that acid-treated platelets may be an alternative to HLA-matched platelets in refractory patients.  The immunogenicity and refractoriness of acid-treated platelets, however, requires further study.

 

Reference

  1. Meinke S, Sandgren P, Mortberg A, Karlstrom C, Kadri N, Wikman A, Hoglund P. Platelets made HLA deficient by acid treatment aggregate normally and escape destruction by complement and phagocytes in the presence of HLA antibodies. Transfusion 2016;56: 370-82.

TRF_CMETransfusion offers CME credit for this study! Log on at www.wileyhealthlearning.com/trf.

Filed Under

  • CME
  • News
  • Platelet Transfusion

Recommended

  • Tranexamic Acid Reduces Risk of Death in Patients with Traumatic Brain Injury

  • New Draft Guidance Recommendations from the FDA to Reduce Risk of Transfusion-Transmitted Creutzfeldt-Jakob Diseases

  • Monitoring Oxygen Saturation and Hemoglobin Values along with Iron and Erythropoietin Supplementation Reduces RBC Transfusion Frequency

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

  • Anemia Treatment Bundle Improves Hemoglobin Recovery after Critical Illness

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley